Last reviewed · How we verify

NCT05725265

LLLT for BCRL: a Randomized, Placebo-controlled Study

Recruiting now NA Last updated 18 October 2024
What this trial tests

NA trial testing Large-area low-level laser therapy(Venusure) in Breast Cancer Lymphedema in 54 participants. Currently enrolling.

Timeline
24 October 2023
Primary endpoint
31 July 2025
31 October 2025

Quick facts

Lead sponsorNational Taiwan University Hospital
PhaseNA
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposetreatment
Enrollment54
Start date24 October 2023
Primary completion31 July 2025
Estimated completion31 October 2025
Sites1 location across Taiwan

Drugs / interventions tested

Conditions studied

Sponsor

National Taiwan University Hospital

Who can join

20 and older, female only, with Breast Cancer Lymphedema. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is conducted to compare between efficacy of large and small area of low-level laser therapy (LLLT) in treatment of post mastectomy lymphedema. The change of severity of BCRL will be measured by the difference of circumference and skin thickness, detected by ultrasound. The influence on clinical symptoms, such as pain, shoulder mobility and hand function, are also investigated in the study.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Breast Cancer Lymphedema

Currently open trials in the same condition.

Other National Taiwan University Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05725265.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing